Personalized mRNA Vaccine (mRNA-4157/V940)

Type: vaccine

Status: FDA Breakthrough Designation. Australia Phase 3.

Developer: Moderna/Merck

Breakthrough Summary

No summary available.

Mechanism of Action

Custom mRNA encoding up to 34 patient-specific neoantigens + Keytruda

Year: 2024-2026